Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

Tardive Dyskinesia Caused by Tetrabenazine

(2013) Peter A. LeWitt   CLINICAL NEUROPHARMACOLOGY

Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder

(2013) Leslie J. Cloud et al.   Neurotherapeutics

New and emerging treatments for symptomatic tardive dyskinesia

(2013) Abdul Qayyum Rana et al.   Drug Design Development and Therapy

Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba

(2012) Xiang Yang Zhang et al.   BIOLOGICAL PSYCHIATRY

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs

(2012) Michael J. Peluso et al.   BRITISH JOURNAL OF PSYCHIATRY

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

(2012) Jack J. Chen et al.   CLINICAL THERAPEUTICS

Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial

(2012) Yusuke Iwata et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Propranolol therapy for tardive dyskinesia revisited

(2012) Stewart A. Factor   MOVEMENT DISORDERS

Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine

(2012) Alcindo Busanello et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Motor Symptoms of Schizophrenia: Is Tardive Dyskinesia a Symptom or Side Effect? A Modern Treatment

(2011) Vladimir Lerner et al.   Current Psychiatry Reports

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders

(2010) David R.P. Guay   American Journal Geriatric Pharmacotherapy

Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice

(2010) Alcindo Busanello et al.   BEHAVIOURAL PHARMACOLOGY

Effects of Amantadine on Tardive Dyskinesia

(2010) Sofia Pappa et al.   CLINICAL NEUROPHARMACOLOGY

Piracetam and Piracetam-Like Drugs

(2010) Andrei G. Malykh et al.   DRUGS

Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians

(2010) Renan P. Souza et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Extract ofGinkgo bilobaTreatment for Tardive Dyskinesia in Schizophrenia

(2010) Wu-Fang Zhang et al.   JOURNAL OF CLINICAL PSYCHIATRY

Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications

(2010) Scott W. Woods et al.   JOURNAL OF CLINICAL PSYCHIATRY

Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo

(2010) Ah-Reum Doo et al.   JOURNAL OF ETHNOPHARMACOLOGY

Spectrum of tardive syndromes: clinical recognition and management

(2010) R. Bhidayasiri et al.   POSTGRADUATE MEDICAL JOURNAL

Pyridoxal Plasma Level in Schizophrenic and Schizoaffective Patients With and Without Tardive Dyskinesia

(2009) Chanoch Miodownik et al.   CLINICAL NEUROPHARMACOLOGY

Tardive dyskinesia and new antipsychotics

(2009) Christoph U Correll et al.   CURRENT OPINION IN PSYCHIATRY

Effects of Levetiracetam on Tardive Dyskinesia

(2009) Scott W. Woods et al.   JOURNAL OF CLINICAL PSYCHIATRY

Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia

(2009) DE Tenback et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder

(2009) Emmanouil N. Rizos et al.   PSYCHIATRIC GENETICS

Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-label study

(2008) Tsuyoshi Miyaoka et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug

(2008) Chun-Rong Li et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Treatment of tardive dyskinesia with levetiracetam in a transplant patient

(2007) S. A. Živković et al.   ACTA NEUROLOGICA SCANDINAVICA